These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16415916)

  • 21. Physician's guide to pharmacovigilance: terminology and causality assessment.
    Rehan HS; Chopra D; Kakkar AK
    Eur J Intern Med; 2009 Jan; 20(1):3-8. PubMed ID: 19237084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project.
    Bousquet PJ; Demoly P; Romano A; Aberer W; Bircher A; Blanca M; Brockow K; Pichler W; Torres MJ; Terreehorst I; Arnoux B; Atanaskovic-Markovic M; Barbaud A; Bijl A; Bonadonna P; Burney PG; Caimmi S; Canonica GW; Cernadas J; Dahlen B; Daures JP; Fernandez J; Gomes E; Gueant JL; Kowalski ML; Kvedariene V; Mertes PM; Martins P; Nizankowska-Mogilnicka E; Papadopoulos N; Ponvert C; Pirmohamed M; Ring J; Salapatas M; Sanz ML; Szczeklik A; Van Ganse E; De Weck AL; Zuberbier T; Merk HF; Sachs B; Sidoroff A;
    Allergy; 2009 Feb; 64(2):194-203. PubMed ID: 19178398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates, osteonecrosis of the jaw, and pharmacovigilance.
    Doogue M
    N Z Med J; 2006 Dec; 119(1246):U2334. PubMed ID: 17151708
    [No Abstract]   [Full Text] [Related]  

  • 24. Free access to pharmacovigilance data.
    Prescrire Int; 2006 Aug; 15(84):138. PubMed ID: 16991216
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacovigilance: what to do if you see an adverse reaction and the consequences.
    Stenver DI
    Eur J Radiol; 2008 May; 66(2):184-6. PubMed ID: 18372136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal.
    P S; P M; Pr S
    Pak J Pharm Sci; 2008 Oct; 21(4):465-7. PubMed ID: 18930872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomics and its implications for autoimmune disease.
    Ross CJ; Katzov H; Carleton B; Hayden MR
    J Autoimmun; 2007; 28(2-3):122-8. PubMed ID: 17418528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics of colorectal cancer prevention and treatment.
    Nguyen H; Tran A; Lipkin S; Fruehauf JP
    Cancer Invest; 2006 Oct; 24(6):630-9. PubMed ID: 16982469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 30. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 32. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
    Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.
    Bondon-Guitton E; Sommet A; Montastruc JL;
    Pharmacopsychiatry; 2009 Mar; 42(2):61-5. PubMed ID: 19308880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new model of pharmacovigilance? A pilot study.
    Zancan A; Locatelli C; Ramella F; Tatoni P; Bacis G; Vecchio S; Manzo L
    Biomed Pharmacother; 2009 Jul; 63(6):451-5. PubMed ID: 18790597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug reactions reporting at a referral hospital in Zimbabwe.
    Khoza S; Madungwe I; Nyambayo P; Mthethwa J; Chikuni O
    Cent Afr J Med; 2004; 50(11-12):104-7. PubMed ID: 16615658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacists' attitudes towards the reporting of suspected adverse drug reactions in Norway.
    Granas AG; Buajordet M; Stenberg-Nilsen H; Harg P; Horn AM
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):429-34. PubMed ID: 16953518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data mining for signals in spontaneous reporting databases: proceed with caution.
    Stephenson WP; Hauben M
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):359-65. PubMed ID: 17019675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.